Hubei Goto Biopharm Co.,Ltd. (SHE:300966)
China · Delayed Price · Currency is CNY 21.37
-0.05 (-0.23%)
Feb 13, 2026, 3:04 PM CST
Hubei Goto Biopharm Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 622.25 | 532.57 | 565.5 | 604.4 | 588.37 | 464.71 |
Other Revenue | 4.03 | 4.03 | 0.9 | 0.17 | 2.52 | 3.41 |
| 626.28 | 536.6 | 566.4 | 604.57 | 590.89 | 468.12 | |
Revenue Growth (YoY) | 14.54% | -5.26% | -6.31% | 2.32% | 26.23% | 0.71% |
Cost of Revenue | 493.22 | 435.71 | 450.29 | 466.77 | 446.63 | 362.21 |
Gross Profit | 133.06 | 100.89 | 116.11 | 137.81 | 144.26 | 105.9 |
Selling, General & Admin | 67.02 | 67.29 | 50.16 | 42.5 | 40.58 | 19.69 |
Research & Development | 70.21 | 51.08 | 38.1 | 45.15 | 37.12 | 21.6 |
Other Operating Expenses | -11.66 | -6.98 | -3.53 | -0.17 | 1.53 | 1.78 |
Operating Expenses | 137.68 | 115.62 | 89.17 | 92.35 | 79.78 | 44.51 |
Operating Income | -4.62 | -14.73 | 26.93 | 45.46 | 64.48 | 61.39 |
Interest Expense | -43.8 | -23.52 | -13.18 | -13.68 | -5.17 | -6.75 |
Interest & Investment Income | 0.68 | 1.05 | 2.39 | 1.92 | 1.19 | 0.64 |
Currency Exchange Gain (Loss) | 1.12 | 1.12 | 1.05 | 2.24 | -0.6 | -0.83 |
Other Non Operating Income (Expenses) | -3.98 | -1.41 | -0.5 | -0.59 | -0.72 | -0.24 |
EBT Excluding Unusual Items | -50.59 | -37.48 | 16.7 | 35.35 | 59.17 | 54.21 |
Gain (Loss) on Sale of Investments | -0.71 | -0.35 | -0.01 | -0.18 | -1.05 | -0.25 |
Gain (Loss) on Sale of Assets | -1.22 | 0.11 | 0.17 | -0.01 | - | -0.01 |
Asset Writedown | -25.79 | -10.46 | -2.23 | -0.96 | -0.06 | -0.5 |
Legal Settlements | - | - | -0.03 | -0.05 | 0.01 | -0.02 |
Other Unusual Items | 5.45 | 2.64 | 4.53 | 4.36 | 28.05 | 6.8 |
Pretax Income | -72.86 | -45.54 | 19.12 | 38.51 | 86.12 | 60.24 |
Income Tax Expense | -20.31 | -13.88 | -2.17 | -1 | 8.05 | 7.05 |
Earnings From Continuing Operations | -52.56 | -31.66 | 21.29 | 39.51 | 78.07 | 53.2 |
Minority Interest in Earnings | 6.69 | 4.07 | 1.72 | 0.69 | 0.26 | 0.09 |
Net Income | -45.86 | -27.59 | 23.01 | 40.21 | 78.33 | 53.29 |
Net Income to Common | -45.86 | -27.59 | 23.01 | 40.21 | 78.33 | 53.29 |
Net Income Growth | - | - | -42.78% | -48.67% | 46.99% | -27.00% |
Shares Outstanding (Basic) | 113 | 115 | 115 | 115 | 106 | 86 |
Shares Outstanding (Diluted) | 113 | 115 | 115 | 115 | 106 | 86 |
Shares Change (YoY) | -4.04% | -0.05% | 0.13% | 8.77% | 22.87% | 0.08% |
EPS (Basic) | -0.40 | -0.24 | 0.20 | 0.35 | 0.74 | 0.62 |
EPS (Diluted) | -0.40 | -0.24 | 0.20 | 0.35 | 0.74 | 0.62 |
EPS Growth | - | - | -42.86% | -52.81% | 19.63% | -27.06% |
Free Cash Flow | -243.93 | -332.2 | -341.12 | -431.98 | -32.91 | -5.09 |
Free Cash Flow Per Share | -2.15 | -2.89 | -2.97 | -3.76 | -0.31 | -0.06 |
Dividend Per Share | - | - | 0.016 | - | 0.136 | - |
Gross Margin | 21.25% | 18.80% | 20.50% | 22.79% | 24.41% | 22.62% |
Operating Margin | -0.74% | -2.74% | 4.75% | 7.52% | 10.91% | 13.11% |
Profit Margin | -7.32% | -5.14% | 4.06% | 6.65% | 13.26% | 11.38% |
Free Cash Flow Margin | -38.95% | -61.91% | -60.23% | -71.45% | -5.57% | -1.09% |
EBITDA | 50.74 | 28.26 | 53.4 | 69.76 | 86.76 | 82.58 |
EBITDA Margin | 8.10% | 5.27% | 9.43% | 11.54% | 14.68% | 17.64% |
D&A For EBITDA | 55.37 | 42.98 | 26.47 | 24.3 | 22.28 | 21.18 |
EBIT | -4.62 | -14.73 | 26.93 | 45.46 | 64.48 | 61.39 |
EBIT Margin | -0.74% | -2.74% | 4.75% | 7.52% | 10.91% | 13.11% |
Effective Tax Rate | - | - | - | - | 9.35% | 11.70% |
Revenue as Reported | 626.28 | 536.6 | 566.4 | 604.57 | 590.89 | 468.12 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.